<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03719573</url>
  </required_header>
  <id_info>
    <org_study_id>123</org_study_id>
    <nct_id>NCT03719573</nct_id>
  </id_info>
  <brief_title>Geriatric Assessment and Intervention in Older Patients Undergoing Surgery for Colorectal Cancer</brief_title>
  <acronym>GEPOC</acronym>
  <official_title>Geriatric Assessment and Intervention in Older Patients Undergoing Surgery for Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Herlev and Gentofte Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Velux Fonden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Herlev and Gentofte Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The GEPOC study investigates the effect of comprehensive geriatric assessment and
      intervention for frail older patients (65 years or older) undergoing elective surgery for
      colorectal cancer. the geriatric intervention will be pre- and postoperative. included in the
      intervention is an exercise intervention.

      The main aim of the study us to see if the functional decline in this group can be reduced.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, controlled trial on frail older patients (aged 65 years or older) with
      colorectal cancer. The patients will be randomized into two groups. The control group will
      receive standard surgical treatment. The intervention group will in addition go through a
      preoperative comprehensive geriatric assessment. The assessment will include evaluation of
      co-morbidity and medication, social status, nutritional status, cognition, depression and
      physical performance. This assessment will form basis of an individualized intervention.
      Patients in the intervention group will participate in planned exercise programs before
      surgery, perioperative and postoperative.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 21, 2019</start_date>
  <completion_date type="Anticipated">July 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Physiotherapist assessing function status.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>30-second chair stand test (30s-CST)</measure>
    <time_frame>baseline to 14 weeks after surgery</time_frame>
    <description>functional test measuring lower body strength</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>physical function and capacity - 6-minute-walk-test</measure>
    <time_frame>baseline to 14 weeks after surgery</time_frame>
    <description>6-minute-walk-test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>physical function and capacity - hand grip strength</measure>
    <time_frame>baseline to 14 weeks after surgery</time_frame>
    <description>hand grip strength</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>physical function and capacity - 6-meter gait speed</measure>
    <time_frame>baseline to 14 weeks after surgery</time_frame>
    <description>6-meter gait speed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported Quality of Life: EORTC</measure>
    <time_frame>baseline to 14 weeks after surgery</time_frame>
    <description>EORTC European Organisation for Research and Treatment of Cancer questionnaire C30 (30-126 points where 30 is the worst)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported Quality of Life: EORTC ELD14</measure>
    <time_frame>baseline to 14 weeks after surgery</time_frame>
    <description>EORTC European Organisation for Research and Treatment of Cancer questionnaire ELD14 (14-54 points where 54 is the worst)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of recovery after surgery: questionnaire</measure>
    <time_frame>1 day before surgery (baseline) to 3 days after surgery</time_frame>
    <description>Measured with the questionnaire: Quality of Recovery - 15 questionnaire (0-150 points where 0 points is the worst)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bodycomposition</measure>
    <time_frame>baseline to 14 weeks after surgery.</time_frame>
    <description>measured by Bioimpedance assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bodycomposition</measure>
    <time_frame>baseline to 14 weeks after surgery.</time_frame>
    <description>measured by dual-energy x-ray absorptiometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflammatory biomarker - CRP</measure>
    <time_frame>baseline to 14 weeks after surgery</time_frame>
    <description>the concentration of CRP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflammatory biomarker - Interleukin 6</measure>
    <time_frame>baseline to 14 weeks after surgery</time_frame>
    <description>the concentration of interleukin 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflammatory biomarker YKL-40</measure>
    <time_frame>baseline to 14 weeks after surgery</time_frame>
    <description>the concentration of YKL-40</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflammatory biomarkers immuno-oncology</measure>
    <time_frame>baseline to 14 weeks after surgery</time_frame>
    <description>the concentration of 92 proteins associated with immuno-oncology (OLink)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sarcopenia biomarker GDF-11</measure>
    <time_frame>baseline to 14 weeks after surgery</time_frame>
    <description>the concentration of GDF-11</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sarcopenia biomarker GDF</measure>
    <time_frame>baseline to 14 weeks after surgery</time_frame>
    <description>the concentration of GDF-15</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative complications</measure>
    <time_frame>30 days</time_frame>
    <description>Measured with Clavien Dindo classification (grade I-V where grade V is death)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>readmission</measure>
    <time_frame>30 days after surgery</time_frame>
    <description>Number of patients being readmitted to hospital within 30 days after operation for colon surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>survival</measure>
    <time_frame>10 years</time_frame>
    <description>number of survivors after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality</measure>
    <time_frame>baseline to 3 months</time_frame>
    <description>number of patients death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of patients to start up of adjuvant chemotherapy after surgery.</measure>
    <time_frame>14 weeks</time_frame>
    <description>according to guidelines, if physical condition allows it (and patient accepts it).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>start up time of adjuvant chemotherapy after surgery</measure>
    <time_frame>14 weeks</time_frame>
    <description>measured in days (if relevant)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of series of adjuvant chemotherapy</measure>
    <time_frame>14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>doses of adjuvant chemotherapy</measure>
    <time_frame>14 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Colon Cancer</condition>
  <condition>Colon Neoplasm</condition>
  <condition>Frail Elderly Syndrome</condition>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Geriatric intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A comprehensive geriatric assessment and intervention, including exercise program.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control.</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Usual treatment and care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Geriatric intervention</intervention_name>
    <description>A comprehensive geriatric assessment (CGA), focusing on co-morbidity, medication, cognitive status, depression, nutritional status and physical status is performed. The intervention is individualized according to the results of the CGA.</description>
    <arm_group_label>Geriatric intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  elective surgery for coloncancer

          -  frail

          -  ability to read and speak danish (informed concent)

        Exclusion Criteria:

          -  any physical condition that hinder physical exercise (eg. no legs)

          -  not able to concent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julia S Johansen, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Professor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Troels G Dolin, MD</last_name>
    <phone>+45 26332809</phone>
    <email>troels.gammeltoft.dolin@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cecilia M Lund, MD, PhD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Herlev and Gentofte Hospital</name>
      <address>
        <city>Herlev</city>
        <state>Region H</state>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Troels G Dolin, MD</last_name>
    </contact>
    <investigator>
      <last_name>Troels G Dolin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 19, 2018</study_first_submitted>
  <study_first_submitted_qc>October 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2018</study_first_posted>
  <last_update_submitted>February 7, 2020</last_update_submitted>
  <last_update_submitted_qc>February 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Herlev and Gentofte Hospital</investigator_affiliation>
    <investigator_full_name>Troels Gammeltoft Dolin</investigator_full_name>
    <investigator_title>MD, Principal Investigator, Department of internal Medicine</investigator_title>
  </responsible_party>
  <keyword>Colon Cancer</keyword>
  <keyword>Frailty</keyword>
  <keyword>Geriatric assessment</keyword>
  <keyword>perioperative care</keyword>
  <keyword>exercise</keyword>
  <keyword>quality of recovery</keyword>
  <keyword>colorectal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>TBA</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

